Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxinkang
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Administration
- Oral
01
Overview
Yangxinkang is a Traditional Chinese Medicine (TCM) formulation, typically administered as a tablet, developed for the treatment of chronic heart failure (CHF) and chronic heart dysfunction. Developed by researchers at The First Hospital Affiliated to Guangzhou University of Traditional Chinese Medicine, it is designed to improve cardiac function and clinical symptoms in patients with heart failure. The formulation generally follows TCM principles of tonifying Qi, nourishing Yin, and promoting blood circulation to resolve stasis. Clinical studies, such as the randomized control trial registered under ChiCTR-TRC-09000549, have evaluated its efficacy and safety as an adjunctive or primary therapy for heart dysfunction, focusing on its ability to improve hemodynamics and patient quality of life.
- Brand names
- Yangxinkang
- Other names
- Yangxinkang TabletsYangxinkang Pian
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on Yangxinkang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yangxinkang.